Therapeutic targets of hypercholesterolemia: HMGCR and LDLR

Abstract

Shizhan Ma,1,2 Wenxiu Sun,3 Ling Gao,1,4,5 Shudong Liu61Department of Endocrinology and Metabolism, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, People’s Republic of China; 2Department of Endocrinology and Metabolism, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, People’s Republic of China; 3Department of Pharmacy, Taishan Vocational College of Nursing, Taian 271000, People’s Republic of China; 4Scientific Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, People’s Republic of China; 5Scientific Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250021, People’s Republic of China; 6Department of Endocrinology, Shandong Rongjun General Hospital, Jinan 250013, People’s Republic of ChinaCorrespondence: Ling GaoScientific Center, Shandong Provincial Hospital Affiliated to Shandong University, 324 Jing 5 Road, Jinan, Shandong Province 250021, People’s Republic of ChinaTel [phone]Email [email protected] LiuDepartment of Endocrinology, Shandong Rongjun General Hospital, 23 Jiefang Road, Jinan, Shandong Province 250013, People’s Republic of ChinaTel [phone]Email [email protected]: Cholesterol homeostasis is critical and necessary for the body’s functions. Hypercholesterolemia can lead to significant clinical problems, such as cardiovascular disease (CVD). 3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) and low–density lipoprotein cholesterol receptor (LDLR) are major points of control in cholesterol homeostasis. We summarize the regulatory mechanisms of HMGCR and LDLR, which may provide insight for new drug design and development.Keywords: cholesterol homeostasis, CVD, HMGCR, LDLR

Keywords

• Cholesterol homeostasis
• CVD
• HMGCR
• LDLR;